A2 Biotherapeutics is a precision therapy platform with a focus on solid cancers and tumors.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/04/2022 | Series B | $143.13MM | $xx.xx | $39.7B | Casdin Capital, Euclidean Capital, Hartford Healthcare Endowment, Nextech Invest, Samsara Biocapital, The Column Group, Uc Investments, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
81,789,831
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Casdin Capital, Euclidean Capital, Hartford Healthcare Endowment, Nextech Invest, Samsara Biocapital, The Column Group, Uc Investments, Vida Ventures
|
||||||
11/05/2019 | Series A | $57MM | $xx.xx | $14.32B | Nextech Invest, Samsara Biocapital, The Column Group, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
57,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Nextech Invest, Samsara Biocapital, The Column Group, Vida Ventures
|
||||||
11/05/2019 | Series A-1 | $7.5MM | $xx.xx | $14.32B | Nextech Invest, Samsara Biocapital, The Column Group, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
6,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Nextech Invest, Samsara Biocapital, The Column Group, Vida Ventures
|